person · Reporting owner

MURRAY JAMES E

Disclosed activity across 3 companies

Tapewire entity: 111888
SEC CIK: 0001018658

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CENTENE CORPCNC · Entity 3133	EVP, Chief Operating Officer	June 23, 2023	June 27, 2023
MAGELLAN HEALTH INCMGLN · Entity 131790	President and COO	January 02, 2022	January 04, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CENTENE CORP

Report date June 23, 2023 · Filed June 27, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2023-06-23	Direct	347.209	Reported balance After 2023-06-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-06-23 · Grant · Acquired 38.865 · Balance 347.209 F2: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3: The phantom stock was acquired by Mr. Murray through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Murray's termination with the Company or on such other date Mr. Murray may elect.
Common StockSEC Table I · non-derivative	Direct	202,853	Reported balance Holding disclosure · report date 2023-06-23 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 202,853 F1: Ownership includes 166,676 shares of restricted stock subject to vesting requirements.
Common StockSEC Table I · non-derivative	IndirectBy trust	30	Reported balance Holding disclosure · report date 2023-06-23 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 30
Common Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.31 · Expires 2030-01-02	Direct	30,683	Reported balance Holding disclosure · report date 2023-06-23 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 30,683

Filing footnotes · ownership attribution and instrument terms

F1: Ownership includes 166,676 shares of restricted stock subject to vesting requirements.

F2: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock.

F3: The phantom stock was acquired by Mr. Murray through regularly scheduled payroll contributions to the Company's deferred compensation plan.

F4: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Murray's termination with the Company or on such other date Mr. Murray may elect.

MAGELLAN HEALTH INC

Report date January 02, 2022 · Filed January 04, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Common Stock, $0.01 par valueSEC Table I · non-derivative	Direct	0	Ending reported balance After 2022-01-04 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2022-01-02 · Exercise / conversion · Acquired 3,262 · Balance 14,074 F1: This transaction was effectuated by a one-third vesting of the Restricted Stock Unit Award granted on January 2, 2020. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. F2: Not applicable. Row 2 · 2022-01-02 · Tax withholding · Disposed 871 · Balance 13,203 F3: Represents the portion of shares withheld by the Issuer in order to pay taxes. F4: Closing price on Nasdaq on December 31, 2021. Row 3 · 2022-01-04 · Disposition to issuer · Disposed 13,203 · Balance 0 F5: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuer's common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration").
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	3,262	Reported balance After 2022-01-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-01-02 · Exercise / conversion · Disposed 3,262 · Balance 3,262 F2: Not applicable. F1: This transaction was effectuated by a one-third vesting of the Restricted Stock Unit Award granted on January 2, 2020. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. F6: The remaining 3,262 Restricted Stock Units vest on January 2, 2023.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2022-01-04 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-01-04 · Disposition to issuer · Disposed 3,262 · Balance 0 F2: Not applicable. F8: These unvested restricted stock units previously granted by the Issuer on January 2, 2020, which provided for vesting on January 2, 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2022-01-04 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-01-04 · Disposition to issuer · Disposed 14,566 · Balance 0 F2: Not applicable. F9: These unvested restricted stock units previously granted by the Issuer on March 4, 2020, which provided for vesting in equal increments on each of March 4, 2022 and 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2022-01-04 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-01-04 · Disposition to issuer · Disposed 28,271 · Balance 0 F2: Not applicable. F10: These unvested restricted stock units previously granted by the Issuer on March 3, 2021, which provided for a one-third vesting of shares on each of March 3, 2022, 2023 and 2024, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $76.64 · Expires 2030-01-02	Direct	0	Reported balance After 2022-01-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-01-04 · Disposition to issuer · Disposed 25,346 · Balance 0 F7: These options previously granted on January 2, 2020, which provided for vesting in 3 equal installments, were disposed of in exchange for a number of options to purchase shares of Centene common stock and at an exercise price per share, in each case, as determined in accordance with the Merger Agreement. The remaining one-third vests on January 2, 2023.
Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2022-01-04 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-01-04 · Disposition to issuer · Disposed 14,006 · Balance 0 F2: Not applicable. F11: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on January 2, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.
Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2022-01-04 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-01-04 · Disposition to issuer · Disposed 18,206 · Balance 0 F2: Not applicable. F12: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on March 4, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effectuated by a one-third vesting of the Restricted Stock Unit Award granted on January 2, 2020. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.

F2: Not applicable.

F3: Represents the portion of shares withheld by the Issuer in order to pay taxes.

F4: Closing price on Nasdaq on December 31, 2021.

F5: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuer's common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration").

F6: The remaining 3,262 Restricted Stock Units vest on January 2, 2023.

F7: These options previously granted on January 2, 2020, which provided for vesting in 3 equal installments, were disposed of in exchange for a number of options to purchase shares of Centene common stock and at an exercise price per share, in each case, as determined in accordance with the Merger Agreement. The remaining one-third vests on January 2, 2023.

F8: These unvested restricted stock units previously granted by the Issuer on January 2, 2020, which provided for vesting on January 2, 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.

F9: These unvested restricted stock units previously granted by the Issuer on March 4, 2020, which provided for vesting in equal increments on each of March 4, 2022 and 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.

F10: These unvested restricted stock units previously granted by the Issuer on March 3, 2021, which provided for a one-third vesting of shares on each of March 3, 2022, 2023 and 2024, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.

F11: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on January 2, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.

F12: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on March 4, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

HUMANA INC

Report date March 30, 2017 · Filed April 03, 2017

Section 16 reporting ended · disclosed 2017-04-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Humana CommonSEC Table I · non-derivative	Direct	34,668	Reported balance After 2017-03-30 transaction · row 1 1 source row Row 1 · 2017-03-30 · Gift · Disposed 121 · Balance 34,668
Phantom Stock UnitsSEC Table II · derivative / convertible security	IndirectSee Footnote	205	Reported balance After 2017-03-31 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-03-31 · Other · Acquired 5 · Balance 205 F7: Phantom Stock Units held for the benefit of reporting person as of March 31, 2017 based on the value of Humana common stock on a 1-for-1 basis, under the Humana Retirement Equalization Plan. The ending number of units reflects normal fluctuation due to changes in stock price.
Humana CommonSEC Table I · non-derivative	IndirectSee Footnote	2,940	Reported balance Holding disclosure · report date 2017-03-30 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 2,940 F6: Shares held in October 2015 GRAT.
Humana CommonSEC Table I · non-derivative	IndirectSee Footnote	29	Reported balance Holding disclosure · report date 2017-03-30 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 29 F1: Shares held for the benefit of reporting person as of February 28, 2017 under the Humana Retirement Savings Plan including routine payroll deductions, quarterly dividend allocation, and a routine disposition of shares to fund an administrative fee assessment under a Tax-Conditioned Plan, exempt under Rule 16b-3(c).
OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $164.65 · Expires 2022-02-24	Direct	10,846	Reported balance Holding disclosure · report date 2017-03-30 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 10,846 F2: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/24/15, vesting in three increments from 02/24/16 to 02/24/18. F8: Any unvested equity will be cancelled as of March 31, 2017 per the Voluntary Release and Separation Agreement signed by Mr. Murray, as filed in the Company's 8-K.
OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $167.81 · Expires 2023-02-18	Direct	21,475	Reported balance Holding disclosure · report date 2017-03-30 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 21,475 F3: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/18/16, vesting in three increments from 02/18/17 to 02/18/19. F8: Any unvested equity will be cancelled as of March 31, 2017 per the Voluntary Release and Separation Agreement signed by Mr. Murray, as filed in the Company's 8-K.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	4,768	Reported balance Holding disclosure · report date 2017-03-30 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance 4,768 F4: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3). F5: Restricted stock units granted to reporting person on 02/18/16, 33% of the award is vesting on 12/15/16, 12/15/17, and 12/15/18. F8: Any unvested equity will be cancelled as of March 31, 2017 per the Voluntary Release and Separation Agreement signed by Mr. Murray, as filed in the Company's 8-K.

Filing footnotes · ownership attribution and instrument terms

F1: Shares held for the benefit of reporting person as of February 28, 2017 under the Humana Retirement Savings Plan including routine payroll deductions, quarterly dividend allocation, and a routine disposition of shares to fund an administrative fee assessment under a Tax-Conditioned Plan, exempt under Rule 16b-3(c).

F2: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/24/15, vesting in three increments from 02/24/16 to 02/24/18.

F3: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/18/16, vesting in three increments from 02/18/17 to 02/18/19.

F4: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3).

F5: Restricted stock units granted to reporting person on 02/18/16, 33% of the award is vesting on 12/15/16, 12/15/17, and 12/15/18.

F6: Shares held in October 2015 GRAT.

F7: Phantom Stock Units held for the benefit of reporting person as of March 31, 2017 based on the value of Humana common stock on a 1-for-1 basis, under the Humana Retirement Equalization Plan. The ending number of units reflects normal fluctuation due to changes in stock price.

F8: Any unvested equity will be cancelled as of March 31, 2017 per the Voluntary Release and Separation Agreement signed by Mr. Murray, as filed in the Company's 8-K.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 23, 2023 Filed Jun 27, 2023 18:42 UTC	CENTENE CORP CNC · Entity 3133	GrantPhantom Stock · Derivative	38.865	$66.80 Strike: $0.00	$2,596.18	Disclosure SEC source: 0001071739-23-000163 · wk-form4_1687905730.xml · derivative · entry 3 MURRAY JAMES E · CIK 0001018658 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347.209 Underlying: Common Stock · 38.865 shares Expires 2023-06-23 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Murray through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Murray's termination with the Company or on such other date Mr. Murray may elect. Read SEC document
June 09, 2023 Filed Jun 13, 2023 18:05 UTC	CENTENE CORP CNC · Entity 3133	GrantPhantom Stock · Derivative	32.762	$67.62 Strike: $0.00	$2,215.37	Disclosure SEC source: 0001071739-23-000159 · wk-form4_1686693929.xml · derivative · entry 3 MURRAY JAMES E · CIK 0001018658 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308.344 Underlying: Common Stock · 32.762 shares Expires 2023-06-09 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Murray through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Murray's termination with the Company or on such other date Mr. Murray may elect. Read SEC document
May 26, 2023 Filed May 31, 2023 18:48 UTC	CENTENE CORP CNC · Entity 3133	GrantPhantom Stock · Derivative	27.286	$63.43 Strike: $0.00	$1,730.75	Disclosure SEC source: 0001071739-23-000153 · wk-form4_1685573315.xml · derivative · entry 3 MURRAY JAMES E · CIK 0001018658 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275.582 Underlying: Common Stock · 27.286 shares Expires 2023-05-26 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Murray through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Murray's termination with the Company or on such other date Mr. Murray may elect. Read SEC document
May 12, 2023 Filed May 12, 2023 18:24 UTC	CENTENE CORP CNC · Entity 3133	GrantPhantom Stock · Derivative	25.691	$67.37 Strike: $0.00	$1,730.80	Disclosure SEC source: 0001071739-23-000144 · wf-form4_168393027873577.xml · derivative · entry 3 MURRAY JAMES E · CIK 0001018658 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248.296 Underlying: Phantom Stock · 25.691 shares Expires 2023-05-12 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Murray through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Murray's termination with the Company or on such other date Mr. Murray may elect. Read SEC document
April 28, 2023 Filed Apr 28, 2023 18:03 UTC	CENTENE CORP CNC · Entity 3133	GrantPhantom Stock · Derivative	25.267	$68.50 Strike: $0.00	$1,730.79	Disclosure SEC source: 0001071739-23-000121 · wf-form4_168271938142284.xml · derivative · entry 3 MURRAY JAMES E · CIK 0001018658 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222.605 Underlying: Phantom Stock · 25.267 shares Expires 2023-04-28 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Murray through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Murray's termination with the Company or on such other date Mr. Murray may elect. Read SEC document
April 14, 2023 Filed Apr 18, 2023 19:40 UTC	CENTENE CORP CNC · Entity 3133	GrantPhantom Stock · Derivative	24.953	$69.36 Strike: $0.00	$1,730.74	Disclosure SEC source: 0001071739-23-000108 · wf-form4_168186122876649.xml · derivative · entry 3 MURRAY JAMES E · CIK 0001018658 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197.338 Underlying: Phantom Stock · 24.953 shares Expires 2023-04-14 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Murray through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Murray's termination with the Company or on such other date Mr. Murray may elect. Read SEC document
March 31, 2023 Filed Apr 4, 2023 21:12 UTC	CENTENE CORP CNC · Entity 3133	GrantPhantom Stock · Derivative	26.988	$64.13 Strike: $0.00	$1,730.74	Disclosure SEC source: 0001071739-23-000098 · wf-form4_168065714295737.xml · derivative · entry 3 MURRAY JAMES E · CIK 0001018658 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172.385 Underlying: Phantom Stock · 26.988 shares Expires 2023-03-31 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Murray through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Murray's termination with the Company or on such other date Mr. Murray may elect. Read SEC document
March 17, 2023 Filed Mar 17, 2023 20:02 UTC	CENTENE CORP CNC · Entity 3133	GrantPhantom Stock · Derivative	27.39	$63.19 Strike: $0.00	$1,730.77	Disclosure SEC source: 0001071739-23-000071 · wf-form4_167909775897728.xml · derivative · entry 4 MURRAY JAMES E · CIK 0001018658 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145.397 Underlying: Phantom Stock · 27.39 shares Expires 2023-03-17 F3 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F4 · shares: The phantom stock was acquired by Mr. Murray through regularly scheduled payroll contributions to the Company's deferred compensation plan. F5 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Murray's termination with the Company or on such other date Mr. Murray may elect. Read SEC document
March 15, 2023 Filed Mar 17, 2023 20:02 UTC	CENTENE CORP CNC · Entity 3133	GrantCommon Stock	67,099	$63.34	$4,250,050.66	Disclosure SEC source: 0001071739-23-000071 · wf-form4_167909775897728.xml · nonDerivative · entry 2 MURRAY JAMES E · CIK 0001018658 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,853 F2 · balance_after: Ownership includes this award of 67,099 restricted stock units. 43,615 units are performance stock units. The number of performance stock units vesting at the end of the three year period is predicated on meeting three-year performance conditions. The remaining 23,484 units will vest in three annual installments on the anniversary of the grant date. In addition, ownership includes 99,577 shares of restricted stock units subject to vesting requirements. Read SEC document
March 15, 2023 Filed Mar 17, 2023 20:02 UTC	CENTENE CORP CNC · Entity 3133	Tax withholdingCommon Stock	466	$63.34	$29,516.44	Disclosure SEC source: 0001071739-23-000071 · wf-form4_167909775897728.xml · nonDerivative · entry 1 MURRAY JAMES E · CIK 0001018658 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,754 F1 · shares: Shares withheld for taxes upon vesting of previously reported stock grant. Read SEC document
March 03, 2023 Filed Mar 6, 2023 19:55 UTC	CENTENE CORP CNC · Entity 3133	GrantPhantom Stock · Derivative	25.234	$68.59 Strike: $0.00	$1,730.80	Disclosure SEC source: 0001071739-23-000055 · wf-form4_167815054325457.xml · derivative · entry 3 MURRAY JAMES E · CIK 0001018658 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118.007 Underlying: Phantom Stock · 25.234 shares Expires 2023-03-03 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Murray through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Murray's termination with the Company or on such other date Mr. Murray may elect. Read SEC document
February 17, 2023 Filed Feb 21, 2023 18:18 UTC	CENTENE CORP CNC · Entity 3133	GrantPhantom Stock · Derivative	23.706	$73.01 Strike: $0.00	$1,730.78	Disclosure SEC source: 0001071739-23-000049 · wf-form4_167702147407452.xml · derivative · entry 3 MURRAY JAMES E · CIK 0001018658 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92.773 Underlying: Phantom Stock · 23.706 shares Expires 2023-02-17 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Murray through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Murray's termination with the Company or on such other date Mr. Murray may elect. Read SEC document
February 08, 2023 Filed Feb 9, 2023 17:07 UTC	CENTENE CORP CNC · Entity 3133	PurchaseCommon Stock	6,750	$73.30	$494,775.00	Disclosure SEC source: 0001071739-23-000030 · wf-form4_167598045096542.xml · nonDerivative · entry 1 MURRAY JAMES E · CIK 0001018658 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,220 F1 · price: The weighted average price for this transaction is reported within the form. Shares were purchased at prices ranging from $73.25 to $73.36. Full information regarding the number of shares at each price is available upon request. F2 · balance_after: Ownership includes 100,761 shares of restricted stock subject to vesting requirements. Read SEC document
February 03, 2023 Filed Feb 7, 2023 21:01 UTC	CENTENE CORP CNC · Entity 3133	GrantPhantom Stock · Derivative	23.85	$72.57 Strike: $0.00	$1,730.79	Disclosure SEC source: 0001071739-23-000026 · wf-form4_167582169844240.xml · derivative · entry 3 MURRAY JAMES E · CIK 0001018658 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69.067 Underlying: Phantom Stock · 23.85 shares Expires 2023-02-03 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Murray through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Murray's termination with the Company or on such other date Mr. Murray may elect. Read SEC document
January 20, 2023 Filed Jan 23, 2023 19:47 UTC	CENTENE CORP CNC · Entity 3133	GrantPhantom Stock · Derivative	22.815	$75.86 Strike: $0.00	$1,730.75	Disclosure SEC source: 0001071739-23-000022 · wf-form4_167452123041474.xml · derivative · entry 3 MURRAY JAMES E · CIK 0001018658 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45.217 Underlying: Phantom Stock · 22.815 shares Expires 2023-01-20 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Murray through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Murray's termination with the Company or on such other date Mr. Murray may elect. Read SEC document
January 06, 2023 Filed Jan 10, 2023 19:53 UTC	CENTENE CORP CNC · Entity 3133	GrantPhantom Stock · Derivative	22.402	$77.26 Strike: $0.00	$1,730.78	Disclosure SEC source: 0001071739-23-000018 · wf-form4_167339839473377.xml · derivative · entry 3 MURRAY JAMES E · CIK 0001018658 · EVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22.402 Underlying: Phantom Stock · 22.402 shares Expires 2023-01-06 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Murray through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Murray's termination with the Company or on such other date Mr. Murray may elect. Read SEC document
January 04, 2022 Filed Jan 4, 2022 17:19 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	Disposition to issuerPerformance-Based Restricted Stock Units · Derivative	18,206	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001209191-22-000998 · doc4.xml · derivative · entry 10 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,206 shares Expires not disclosed F2 · derivative.exercise_price: Not applicable. F12 · price: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on March 4, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F12 · derivative.exercise_date: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on March 4, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F2 · derivative.expiration_date: Not applicable. Read SEC document
January 04, 2022 Filed Jan 4, 2022 17:19 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	Disposition to issuerPerformance-Based Restricted Stock Units · Derivative	14,006	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001209191-22-000998 · doc4.xml · derivative · entry 9 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,006 shares Expires not disclosed F2 · derivative.exercise_price: Not applicable. F11 · price: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on January 2, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F11 · derivative.exercise_date: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on January 2, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F2 · derivative.expiration_date: Not applicable. Read SEC document
January 04, 2022 Filed Jan 4, 2022 17:19 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	Disposition to issuerRestricted Stock Units · Derivative	28,271	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001209191-22-000998 · doc4.xml · derivative · entry 8 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,271 shares Expires not disclosed F2 · derivative.exercise_price: Not applicable. F10 · price: These unvested restricted stock units previously granted by the Issuer on March 3, 2021, which provided for a one-third vesting of shares on each of March 3, 2022, 2023 and 2024, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F10 · derivative.exercise_date: These unvested restricted stock units previously granted by the Issuer on March 3, 2021, which provided for a one-third vesting of shares on each of March 3, 2022, 2023 and 2024, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F2 · derivative.expiration_date: Not applicable. Read SEC document
January 04, 2022 Filed Jan 4, 2022 17:19 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	Disposition to issuerRestricted Stock Units · Derivative	14,566	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001209191-22-000998 · doc4.xml · derivative · entry 7 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,566 shares Expires not disclosed F2 · derivative.exercise_price: Not applicable. F9 · price: These unvested restricted stock units previously granted by the Issuer on March 4, 2020, which provided for vesting in equal increments on each of March 4, 2022 and 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F9 · derivative.exercise_date: These unvested restricted stock units previously granted by the Issuer on March 4, 2020, which provided for vesting in equal increments on each of March 4, 2022 and 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F2 · derivative.expiration_date: Not applicable. Read SEC document
January 04, 2022 Filed Jan 4, 2022 17:19 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	Disposition to issuerRestricted Stock Units · Derivative	3,262	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001209191-22-000998 · doc4.xml · derivative · entry 6 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,262 shares Expires not disclosed F2 · derivative.exercise_price: Not applicable. F8 · price: These unvested restricted stock units previously granted by the Issuer on January 2, 2020, which provided for vesting on January 2, 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F8 · derivative.exercise_date: These unvested restricted stock units previously granted by the Issuer on January 2, 2020, which provided for vesting on January 2, 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F2 · derivative.expiration_date: Not applicable. Read SEC document
January 04, 2022 Filed Jan 4, 2022 17:19 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	Disposition to issuerStock Options · Derivative	25,346	Not disclosed Strike: $76.64	Not disclosed	Disclosure SEC source: 0001209191-22-000998 · doc4.xml · derivative · entry 5 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,346 shares Expires 2030-01-02 F7 · price: These options previously granted on January 2, 2020, which provided for vesting in 3 equal installments, were disposed of in exchange for a number of options to purchase shares of Centene common stock and at an exercise price per share, in each case, as determined in accordance with the Merger Agreement. The remaining one-third vests on January 2, 2023. F7 · derivative.exercise_date: These options previously granted on January 2, 2020, which provided for vesting in 3 equal installments, were disposed of in exchange for a number of options to purchase shares of Centene common stock and at an exercise price per share, in each case, as determined in accordance with the Merger Agreement. The remaining one-third vests on January 2, 2023. Read SEC document
January 04, 2022 Filed Jan 4, 2022 17:19 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	Disposition to issuerOrdinary Common Stock, $0.01 par value	13,203	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-000998 · doc4.xml · nonDerivative · entry 3 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · kind: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuer's common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration"). F5 · price: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuer's common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration"). Read SEC document
January 02, 2022 Filed Jan 4, 2022 17:19 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	Exercise / conversionRestricted Stock Units · Derivative	3,262	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001209191-22-000998 · doc4.xml · derivative · entry 4 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,262 Underlying: Common Stock · 3,262 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not applicable. F1 · kind: This transaction was effectuated by a one-third vesting of the Restricted Stock Unit Award granted on January 2, 2020. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. F2 · price: Not applicable. F6 · derivative.exercise_date: The remaining 3,262 Restricted Stock Units vest on January 2, 2023. F2 · derivative.expiration_date: Not applicable. Read SEC document
January 02, 2022 Filed Jan 4, 2022 17:19 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	Tax withholdingOrdinary Common Stock, $0.01 par value	871	$94.99	$82,736.29	Disclosure SEC source: 0001209191-22-000998 · doc4.xml · nonDerivative · entry 2 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,203 F3 · kind: Represents the portion of shares withheld by the Issuer in order to pay taxes. F4 · price: Closing price on Nasdaq on December 31, 2021. Read SEC document
January 02, 2022 Filed Jan 4, 2022 17:19 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	Exercise / conversionOrdinary Common Stock, $0.01 par value	3,262	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-000998 · doc4.xml · nonDerivative · entry 1 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effectuated by a one-third vesting of the Restricted Stock Unit Award granted on January 2, 2020. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. F2 · price: Not applicable. Read SEC document
March 04, 2021 Filed Mar 5, 2021 18:47 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	Exercise / conversionRestricted Stock Units · Derivative	7,284	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-21-018371 · doc4.xml · derivative · entry 4 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,566 Underlying: Common Stock · 7,284 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not applicable. F1 · kind: This transaction was effectuated by a one-third vesting of the Restricted Stock Unit award granted on March 4, 2020. Each Restricted Stock Unit represents a contingent right to receive one share of Magellan common stock. F2 · price: Not applicable. F6 · derivative.exercise_date: The remainder of 14,566 Restricted Stock Units shall vest in equal increments on March 4, 2022 and 2023, subject to earlier acceleration or forfeiture. F2 · derivative.expiration_date: Not applicable. Read SEC document
March 04, 2021 Filed Mar 5, 2021 18:47 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	Tax withholdingOrdinary Common Stock, $0.01 par value	2,866	$93.47	$267,885.02	Disclosure SEC source: 0001209191-21-018371 · doc4.xml · nonDerivative · entry 2 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,812 F3 · kind: Represents the portion of shares withheld by the Company in order to pay taxes. F4 · price: Closing price on NASDAQ on March 4, 2021. Read SEC document
March 04, 2021 Filed Mar 5, 2021 18:47 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	Exercise / conversionOrdinary Common Stock, $0.01 par value	7,284	$0.00	$0.00	Disclosure SEC source: 0001209191-21-018371 · doc4.xml · nonDerivative · entry 1 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effectuated by a one-third vesting of the Restricted Stock Unit award granted on March 4, 2020. Each Restricted Stock Unit represents a contingent right to receive one share of Magellan common stock. F2 · price: Not applicable. Read SEC document
March 03, 2021 Filed Mar 5, 2021 18:47 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	GrantRestricted Stock Units · Derivative	28,271	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-21-018371 · doc4.xml · derivative · entry 3 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,271 Underlying: Common Stock · 28,271 shares Expires not disclosed F2 · derivative.exercise_price: Not applicable. F2 · price: Not applicable. F5 · derivative.exercise_date: Restricted Stock Units vest in one third increments on March 3rd of each of 2022, 2023 and 2024, subject to earlier acceleration or forfeiture. F2 · derivative.expiration_date: Not applicable. Read SEC document
January 02, 2021 Filed Jan 5, 2021 17:24 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	Exercise / conversionRestricted Stock Units · Derivative	3,262	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-21-001316 · doc4.xml · derivative · entry 3 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,524 Underlying: Common Stock · 3,262 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not applicable. F1 · kind: This transaction was effectuated by a one-third vesting of the Restricted Stock Unit Award granted on January 2, 2020. Each Restricted Stock Unit represents a contingent right to receive one share of Magellan common stock. F2 · price: Not applicable. F5 · derivative.exercise_date: The remainder of 6,524 Restricted Stock Units shall vest in equal increments on January 2, 2022 and 2023. F2 · derivative.expiration_date: Not applicable. F5 · balance_after: The remainder of 6,524 Restricted Stock Units shall vest in equal increments on January 2, 2022 and 2023. Read SEC document
January 02, 2021 Filed Jan 5, 2021 17:24 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	Tax withholdingOrdinary Common Stock, $0.01 par value	1,368	$82.84	$113,325.12	Disclosure SEC source: 0001209191-21-001316 · doc4.xml · nonDerivative · entry 2 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,394 F3 · kind: Represents the portion of shares withheld by the Company in order to pay taxes. F4 · price: Closing price on NASDAQ on December 31, 2020. Read SEC document
January 02, 2021 Filed Jan 5, 2021 17:24 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	Exercise / conversionOrdinary Common Stock, $0.01 par value	3,262	$0.00	$0.00	Disclosure SEC source: 0001209191-21-001316 · doc4.xml · nonDerivative · entry 1 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effectuated by a one-third vesting of the Restricted Stock Unit Award granted on January 2, 2020. Each Restricted Stock Unit represents a contingent right to receive one share of Magellan common stock. F2 · price: Not applicable. Read SEC document
May 15, 2020 Filed May 19, 2020 18:48 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	PurchaseOrdinary Common Stock, $0.01 par value	4,500	$67.63	$304,317.45	Disclosure SEC source: 0001209191-20-030694 · doc4.xml · nonDerivative · entry 1 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 F1 · price: The number of securities reported were purchased in multiple open market transactions at an average price of $67.6261. The Reporting Person undertakes to provide staff of the SEC, the issuer, or a stockholder of the issuer, upon request, the number of shares purchased by the Reporting Person at each separate price. Read SEC document
March 04, 2020 Filed Mar 6, 2020 16:17 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	GrantRestricted Stock Units · Derivative	21,850	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-20-016907 · doc4.xml · derivative · entry 2 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,850 Underlying: Common Stock · 21,850 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F1 · price: Not applicable. F4 · derivative.exercise_date: Restricted Stock Units vest in one third increments on March 4th of each of 2021, 2022 and 2023. F1 · derivative.expiration_date: Not applicable. Read SEC document
March 04, 2020 Filed Mar 6, 2020 16:17 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	GrantPerformance-Based Restricted Stock Units · Derivative	18,206	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-20-016907 · doc4.xml · derivative · entry 1 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,206 Underlying: Common Stock · 18,206 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F1 · price: Not applicable. F2 · derivative.expiration_date: On the third anniversary of the grant date, Performance-Based Restricted Stock Units ("PSUs") vest based on achievement of total shareholder return ("TSR") performance relative to the S&P Health Services Industry Index over a three-year period beginning in 2020 and ending in 2022. Payout for vested PSUs ranges from 0% to 200% of the indicated number of shares, based on the Company's TSR percentile ranking compared to the TSR of the companies included in the selected market index. TSR is measured generally as the increase or decrease in the market value of the Company common stock with a deemed reinvestment of any dividends. If a participant terminates employment prior to the third anniversary of the grant date, the PSUs generally will be forfeited. PSUs have no voting rights and are generally non-transferable. The indicated number of PSUs assumes 100% vesting, and the actual number of shares issued in settlement of the PSUs may be greater or less than the indicated number. F3 · derivative.expiration_date: (Continuation of Footnote 3) - Since the payout for PSUs can range from 0% to 200%, the maximum number of shares that could vest and be issued could be double the indicated number. Read SEC document
January 02, 2020 Filed Jan 6, 2020 11:17 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	GrantStock Options (right to buy) · Derivative	25,346	$0.00 Strike: $76.64	$0.00	Disclosure SEC source: 0001209191-20-001549 · doc4.xml · derivative · entry 3 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,346 Underlying: Common Stock · 25,346 shares Expires 2030-01-02 F5 · derivative.exercise_date: Stock Options shall vest and become exercisable in one-third increments on each of January 2 of 2021, 2022 and 2023. Read SEC document
January 02, 2020 Filed Jan 6, 2020 11:17 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	GrantPerformance Stock Units · Derivative	14,006	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-20-001549 · doc4.xml · derivative · entry 2 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,006 Underlying: Common Stock · 14,006 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F1 · price: Not applicable. F3 · derivative.expiration_date: On the third anniversary of the grant date, Performance-Based Restricted Stock Units ("PSUs") vest and are settled as of January 10, 2023 based on achievement of total shareholder return ("TSR") performance over a three-year period beginning January 1, 2020 and ending December 31, 2022. Payout for vested PSUs ranges from 0% to 200% of the indicated number of shares, based on the Company's TSR percentile ranking compared to the TSR of the companies included in the selected market index. TSR is measured generally as the increase or decrease in the market value of the Company common stock with a deemed reinvestment of any dividends. If a participant terminates employment prior to the third anniversary of the grant date, the PSUs generally will be forfeited. PSUs have no voting rights and are generally non-transferable. The indicated number of PSUs assumes 100% vesting, and the actual number of shares issued in settlement of the PSUs may be greater or less than the indicated number. F4 · derivative.expiration_date: (Continuation of Footnote 3) - Since the payout for PSUs can range from 0% to 200%, the maximum number of shares that could vest and be issued could be double the indicated number. Read SEC document
January 02, 2020 Filed Jan 6, 2020 11:17 UTC	MAGELLAN HEALTH INC MGLN · Entity 131790	GrantRestricted Stock Units · Derivative	9,786	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-20-001549 · doc4.xml · derivative · entry 1 MURRAY JAMES E · CIK 0001018658 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,786 Underlying: Common Stock · 9,786 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F1 · price: Not applicable. F2 · derivative.exercise_date: Restricted Stock Units shall vest and become exercisable in one-third increments on January 2 of each of 2021, 2022 and 2023. F1 · derivative.expiration_date: Not applicable. Read SEC document
March 31, 2017 Filed Apr 3, 2017 21:05 UTC	HUMANA INC HUM · Entity 1429	OtherPhantom Stock Units · Derivative	5	$201.66	$1,008.30	Disclosure SEC source: 0000049071-17-000090 · edgar.xml · derivative · entry 7 MURRAY JAMES E · CIK 0001018658 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 205 Underlying: Humana Common · 5 shares Expires not disclosed F7 · security: Phantom Stock Units held for the benefit of reporting person as of March 31, 2017 based on the value of Humana common stock on a 1-for-1 basis, under the Humana Retirement Equalization Plan. The ending number of units reflects normal fluctuation due to changes in stock price. F7 · derivative.exercise_price: Phantom Stock Units held for the benefit of reporting person as of March 31, 2017 based on the value of Humana common stock on a 1-for-1 basis, under the Humana Retirement Equalization Plan. The ending number of units reflects normal fluctuation due to changes in stock price. F7 · derivative.exercise_date: Phantom Stock Units held for the benefit of reporting person as of March 31, 2017 based on the value of Humana common stock on a 1-for-1 basis, under the Humana Retirement Equalization Plan. The ending number of units reflects normal fluctuation due to changes in stock price. F7 · derivative.expiration_date: Phantom Stock Units held for the benefit of reporting person as of March 31, 2017 based on the value of Humana common stock on a 1-for-1 basis, under the Humana Retirement Equalization Plan. The ending number of units reflects normal fluctuation due to changes in stock price. F7 · ownership.nature: Phantom Stock Units held for the benefit of reporting person as of March 31, 2017 based on the value of Humana common stock on a 1-for-1 basis, under the Humana Retirement Equalization Plan. The ending number of units reflects normal fluctuation due to changes in stock price. Read SEC document
March 30, 2017 Filed Apr 3, 2017 21:05 UTC	HUMANA INC HUM · Entity 1429	GiftHumana Common	121	$0.00	$0.00	Disclosure SEC source: 0000049071-17-000090 · edgar.xml · nonDerivative · entry 1 MURRAY JAMES E · CIK 0001018658 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,668 Read SEC document
March 21, 2017 Filed Mar 23, 2017 20:46 UTC	HUMANA INC HUM · Entity 1429	OtherPhantom Stock Units · Derivative	200	$213.55	$42,710.00	Disclosure SEC source: 0000049071-17-000087 · edgar.xml · derivative · entry 7 MURRAY JAMES E · CIK 0001018658 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 200 Underlying: Humana Common · 200 shares Expires not disclosed F7 · security: Phantom Stock Units held for the benefit of reporting person as of March 21, 2017 based on the value of Humana common stock on a 1-for-1 basis, under the Humana Retirement Equalization Plan. The ending number of units reflects normal fluctuation due to changes in stock price. F7 · derivative.exercise_price: Phantom Stock Units held for the benefit of reporting person as of March 21, 2017 based on the value of Humana common stock on a 1-for-1 basis, under the Humana Retirement Equalization Plan. The ending number of units reflects normal fluctuation due to changes in stock price. F7 · derivative.exercise_date: Phantom Stock Units held for the benefit of reporting person as of March 21, 2017 based on the value of Humana common stock on a 1-for-1 basis, under the Humana Retirement Equalization Plan. The ending number of units reflects normal fluctuation due to changes in stock price. F7 · derivative.expiration_date: Phantom Stock Units held for the benefit of reporting person as of March 21, 2017 based on the value of Humana common stock on a 1-for-1 basis, under the Humana Retirement Equalization Plan. The ending number of units reflects normal fluctuation due to changes in stock price. F7 · ownership.nature: Phantom Stock Units held for the benefit of reporting person as of March 21, 2017 based on the value of Humana common stock on a 1-for-1 basis, under the Humana Retirement Equalization Plan. The ending number of units reflects normal fluctuation due to changes in stock price. Read SEC document
March 06, 2017 Filed Mar 7, 2017 21:06 UTC	HUMANA INC HUM · Entity 1429	Exercise / conversionOptions · Derivative	10,846	$0.00 Strike: $164.65	$0.00	Disclosure SEC source: 0000049071-17-000059 · edgar.xml · derivative · entry 6 MURRAY JAMES E · CIK 0001018658 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,846 Underlying: Humana Common · 10,846 shares Expires 2022-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/24/15, vesting in three increments from 02/24/16 to 02/24/18. F2 · derivative.exercise_date: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/24/15, vesting in three increments from 02/24/16 to 02/24/18. Read SEC document
March 06, 2017 Filed Mar 7, 2017 21:06 UTC	HUMANA INC HUM · Entity 1429	SaleHumana Common	12,407	$213.65	$2,650,805.18	Disclosure SEC source: 0000049071-17-000059 · edgar.xml · nonDerivative · entry 4 MURRAY JAMES E · CIK 0001018658 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F9 · price: Shares sold at prices ranging from $213.34 to $213.92. F7 · ownership.nature: Shares held in October 2016 GRAT. Read SEC document
March 06, 2017 Filed Mar 7, 2017 21:06 UTC	HUMANA INC HUM · Entity 1429	SaleHumana Common	7,898	$213.65	$1,687,425.08	Disclosure SEC source: 0000049071-17-000059 · edgar.xml · nonDerivative · entry 3 MURRAY JAMES E · CIK 0001018658 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,940 F9 · price: Shares sold at prices ranging from $213.34 to $213.92. F6 · ownership.nature: Shares held in October 2015 GRAT. Read SEC document
March 06, 2017 Filed Mar 7, 2017 21:06 UTC	HUMANA INC HUM · Entity 1429	SaleHumana Common	10,846	$213.55	$2,316,148.12	Disclosure SEC source: 0000049071-17-000059 · edgar.xml · nonDerivative · entry 2 MURRAY JAMES E · CIK 0001018658 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,789 F8 · price: Shares sold at prices ranging from $213.34 to $213.84. Read SEC document
March 06, 2017 Filed Mar 7, 2017 21:06 UTC	HUMANA INC HUM · Entity 1429	Exercise / conversionHumana Common	10,846	$164.65	$1,785,739.67	Disclosure SEC source: 0000049071-17-000059 · edgar.xml · nonDerivative · entry 1 MURRAY JAMES E · CIK 0001018658 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 22, 2017 Filed Feb 23, 2017 02:06 UTC	HUMANA INC HUM · Entity 1429	OtherPhantom Stock Units · Derivative	3,808	$205.34	$781,934.72	Disclosure SEC source: 0000049071-17-000038 · edgar.xml · derivative · entry 21 MURRAY JAMES E · CIK 0001018658 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Humana Common · 3,808 shares Expires not disclosed F11 · security: Phantom Stock Units (based on the value of Humana common stock) held for the benefit of reporting person as of January 31, 2017, under the Humana Retirement Equalization Plan. The ending number of units reflects normal fluctuation due to changes in stock price. F11 · derivative.exercise_price: Phantom Stock Units (based on the value of Humana common stock) held for the benefit of reporting person as of January 31, 2017, under the Humana Retirement Equalization Plan. The ending number of units reflects normal fluctuation due to changes in stock price. F22 · price: Shares sold at closing price on 2/21/2017. F11 · derivative.exercise_date: Phantom Stock Units (based on the value of Humana common stock) held for the benefit of reporting person as of January 31, 2017, under the Humana Retirement Equalization Plan. The ending number of units reflects normal fluctuation due to changes in stock price. F11 · derivative.expiration_date: Phantom Stock Units (based on the value of Humana common stock) held for the benefit of reporting person as of January 31, 2017, under the Humana Retirement Equalization Plan. The ending number of units reflects normal fluctuation due to changes in stock price. F11 · ownership.nature: Phantom Stock Units (based on the value of Humana common stock) held for the benefit of reporting person as of January 31, 2017, under the Humana Retirement Equalization Plan. The ending number of units reflects normal fluctuation due to changes in stock price. Read SEC document
February 22, 2017 Filed Feb 23, 2017 02:06 UTC	HUMANA INC HUM · Entity 1429	OtherHumana Common	1,685	$205.34	$345,997.90	Disclosure SEC source: 0000049071-17-000038 · edgar.xml · nonDerivative · entry 15 MURRAY JAMES E · CIK 0001018658 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F22 · price: Shares sold at closing price on 2/21/2017. F3 · ownership.nature: Shares held for the benefit of reporting person as of January 31, 2017 under the Humana Retirement Savings Plan including routine payroll deductions, quarterly dividend allocation, and a routine disposition of shares to fund an administrative fee assessment under a Tax-Conditioned Plan, exempt under Rule 16b-3(c). Read SEC document
February 22, 2017 Filed Feb 23, 2017 02:06 UTC	HUMANA INC HUM · Entity 1429	SaleHumana Common	9,523	$204.69	$1,949,216.21	Disclosure SEC source: 0000049071-17-000038 · edgar.xml · nonDerivative · entry 8 MURRAY JAMES E · CIK 0001018658 · EVP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,932 F15 · price: Shares sold at a prices ranging from $204.31 to $204.89. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.